Estrogen regulation of apoptosis in osteoblasts

被引:63
作者
Bradford, Peter G. [1 ]
Gerace, Ken V. [1 ]
Roland, Renee L. [1 ]
Chrzan, Brian G. [1 ]
机构
[1] SUNY Buffalo, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA
关键词
Apoptosis; Estrogen receptor; Inositol trisphosphate receptor; Caspase-3/7; Osteoporosis; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; HORMONE REPLACEMENT THERAPY; RANDOMIZED CONTROLLED TRIAL; BONE-MINERAL DENSITY; BISPHOSPHONATES; CALCIUM; DEATH; CELLS; OSTEONECROSIS; MODULATION;
D O I
10.1016/j.physbeh.2009.04.025
中图分类号
B84 [心理学];
学科分类号
010107 [宗教学];
摘要
Dysregulated apoptosis is a critical failure associated with prominent degenerative diseases including osteoporosis. In bone, estrogen deficiency has been associated with accelerated osteoblast apoptosis and susceptibility to osteoporotic fractures. Hormone therapy continues to be an effective option for preventing osteoporosis and bone fractures. Induction of apoptosis in G-292 human osteoblastic cells by exposure to etoposide or the inflammatory cytokine TNF-alpha promoted acute caspase-3/7 activity and this increased activity was inhibited by pretreatment with estradiol. Etoposide also increased the expression of a battery of apoptosis-promoting genes and this expression was also inhibited by estradiol. Among the apoptotic genes whose expression was inhibited by estradiol was ITPR1, which encodes the type 1 InsP3R. InsP3Rs are intracellular calcium channels and key proapoptotic mediators. Estradiol via estrogen receptor beta 1 suppresses ITPR1 gene transcription in G-292 cells. These analyses suggest that an underlying basis of the beneficial activity of estrogens in combating osteoporosis may involve the prevention of apoptosis in osteoblasts and that a key event in this process is the repression of apoptotic gene expression and inhibition of caspase-3/7. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:181 / 185
页数:5
相关论文
共 27 条
[1]
Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures:: the PERF study [J].
Bagger, YZ ;
Tankó, LB ;
Alexandersen, P ;
Hansen, HB ;
Mollgaard, A ;
Ravn, P ;
Qvist, P ;
Kanis, JA ;
Christiansen, C .
BONE, 2004, 34 (04) :728-735
[2]
Boehning D, 2004, CELL CYCLE, V3, P252
[3]
Boyce Brendan F., 2005, Keio Journal of Medicine, V54, P127, DOI 10.2302/kjm.54.127
[4]
Bradford Peter G., 2000, Molecular Cell Biology Research Communications, V3, P73, DOI 10.1006/mcbr.2000.0194
[5]
Effects of hormone therapy on bone mineral density - Results from the postmenopausal estrogen/progestin interventions (PEPI) trial [J].
Bush, TL ;
Wells, HB ;
James, MK ;
BarrettConnor, E ;
Marcus, R ;
Greendale, G ;
Hunsberger, S ;
McGowan, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (17) :1389-1396
[6]
Death receptors in chemotherapy and cancer [J].
Debatin, KM ;
Krammer, PH .
ONCOGENE, 2004, 23 (16) :2950-2966
[7]
DeJong RS, 1995, ANTICANCER RES, V15, P2319
[8]
Bone morphogenetic protein-2 promotes osteoblast apoptosis through a Smad-independent, protein kinase C-dependent signaling pathway [J].
Haÿ, E ;
Lemonnier, J ;
Fromigué, O ;
Marie, PJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (31) :29028-29036
[9]
T cells deficient in inositol 1,4,5-trisphosphate receptor are resistant to apoptosis [J].
Jayaraman, T ;
Marks, AR .
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (06) :3005-3012
[10]
Cloning and characterization of the type I inositol 1,4,5-trisphosphate receptor gene promoter - Regulation by 17 beta-estradiol in osteoblasts [J].
Kirkwood, KL ;
Homick, K ;
Dragon, MB ;
Bradford, PG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (36) :22425-22431